Narrow search
Showing 1 - 10 of 13,796
Cover Image
Science, Scarcity and Public Health : The Search for New Pharma Models
Abbott, Frederick M. - 2015
These are neither the best of times nor the worst of times for the pharmaceutical industry, or for global public health. Media reports regarding recent legal developments would suggest that the originator pharmaceutical industry is facing a new and dangerous threat to its long-term welfare,...
Persistent link: https://www.econbiz.de/10014141859
Cover Image
Achieving dynamic efficiency in pharmaceutical innovation : identifying the optimal share of value and payments required
Woods, Beth; Lomas, James; Sculpher, Mark; Weatherly, Helen - In: Health economics 33 (2024) 4, pp. 804-819
Persistent link: https://www.econbiz.de/10014514558
Cover Image
The shortage of medical workers in Sub-Saharan Africa and substitution policy
Bourgain, Arnaud (contributor);  … - 2008
merits and drawbacks of substitution policies by developing a simple growth model of healthcare productivity with medical …
Persistent link: https://www.econbiz.de/10003792882
Cover Image
Parallel Trade in Pharmaceuticals : Trade Therapy for Market Distortions
Abbott, Frederick M. - 2017
, particularly from an economic standpoint. In this regard, pharmaceuticals are not generally traded in what might be described as a … because it is imported. Parallel trade (i.e., imports and exports) in pharmaceuticals takes place in markets that are … international exhaustion. This should help to facilitate price reductions in the global market for pharmaceuticals …
Persistent link: https://www.econbiz.de/10014124812
Cover Image
Health, Health Care, and Incompletely Theorized Agreements : A Normative Theory of Health Policy Decision Making
Prah Ruger, Jennifer - 2010
The years 2003-2004 marked the tenth anniversary of the rapid rise and demise of the Clinton administration's health reform efforts. Health reform may again be a political issue in the 2008 congressional and presidential elections. However, analysts still disagree over why large-scale health...
Persistent link: https://www.econbiz.de/10012760380
Cover Image
Population-Level Intervention and Information Collection in Dynamic Healthcare Policy
Cipriano, Lauren - 2017
We develop a general framework for optimal health policy design in a dynamic setting. We consider a hypothetical medical intervention for a cohort of patients where one parameter varies across cohorts with imperfectly observable linear dynamics. We seek to identify the optimal time to change the...
Persistent link: https://www.econbiz.de/10012948117
Cover Image
A Welfare Analysis of Rationing in Health Care Provision
Levaggi, Laura; Levaggi, Rosella - 2016
We study the welfare properties of direct restrictions based on cost-effectiveness against indirect methods represented by waiting lists in a public health care system. Health care is supplied for free, but with some restrictions by the public health sector. Patients can choose to address their...
Persistent link: https://www.econbiz.de/10014128611
Cover Image
Does increased price competition reduce entry of new pharmaceutical products?
Granlund, David; Rudholm, Niklas - In: Advances in management & applied economics 1 (2011) 1, pp. 1-14
In October 2002, a substitution reform was introduced in the Swedish pharmaceuticals market. In this paper, the effects …
Persistent link: https://www.econbiz.de/10009240823
Cover Image
Valuation of Intangible Assets : Estimating Late-Stage Development Cost of Pharmaceutical R&D
Favato, Giampiero; Mills, Roger - 2014
Policy makers need reliable estimates of direct costs of pharmaceutical R&D, in order to contain health-care costs and at the same time maintain a supportive environment for investment in research. This paper evaluates the application of parametric estimating methods to the late stage clinical...
Persistent link: https://www.econbiz.de/10014224317
Cover Image
Evaluation and Learning in R&D Investment
Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023
We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...
Persistent link: https://www.econbiz.de/10014287391